How much cash does Aclaris Therapeutics generate?

Aclaris Therapeutics (ACRS) generated -$52.2M in operating cash flow over the trailing twelve months.

What is Aclaris Therapeutics's free cash flow?

After $81.0K of capital expenditures, Aclaris Therapeutics's free cash flow was -$52.3M over the trailing twelve months, up 5.4% year over year.

Where does Aclaris Therapeutics's cash flow data come from?

Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Aclaris Therapeutics ACRS Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$69.66M-7.3%	-$64.92M+54.2%	-$141.68M-5.2%	-$134.65M-3.4%	-$130.21M+1.4%
Depreciation and amortization	$428K-5.7%	$454K-8.3%	$495K-12.2%	$564K-18.5%	$692K-14.3%
Stock-based compensation	$12.05M-2.7%	$12.38M+0.5%	$12.32M-1.2%	$12.46M+1.3%	$12.3M+13.3%
Change in accounts payable	$8.3M-1.8%	$8.45M+459%	$1.51M+33.2%	$1.14M+123%	-$4.85M-5.9%
Change in accrued liabilities	——	——	——	——	——
Change in deferred revenue	-$3.84M-0.6%	-$3.82M-210%	$3.47M-65.9%	$10.17M-40.6%	$17.11M-28.5%
Change in fair value of contingent consideration	——	$2.3M—	——	——	——
Net cash from operating activities	-$52.21M-10.8%	-$47.11M-9.8%	-$42.92M—	——	——
Capital expenditures	$81K-27.0%	$111K—	——	——	——
Net cash from investing activities	-$1.69M-103%	$48.37M+195%	-$50.73M+17.9%	-$61.76M+8.5%	-$67.48M+3.3%
Proceeds from issuance of common stock	——	——	——	——	——
Taxes paid for net share settlement	$421K-5.6%	$446K-27.7%	$617K-1.6%	$627K-0.3%	$629K+53.8%
Net cash from financing activities	$52.19M+990%	-$5.86M-108%	$71.25M-4.1%	$74.32M0.0%	$74.32M-0.3%
Net increase (decrease) in cash	——	——	——	——	-$5.48M+64.2%
Contingent consideration fair value adjustments	——	$2.3M—	——	——	——
In Process Research And Development Expense	——	——	——	——	——
Increase Decrease In Accounts Receivable Prepaid Expense And Other Assets	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	——	——
Payment Of Deferred Transactions Consideration To Acquire Intangible Assets	——	——	——	——	——
Sale Of Stock Consideration Received On Transaction	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Deferred Transaction Consideration In Connection With In License Agreement	——	——	——	——	——
Fair Value Of Warrants Issued In Connection With In License Agreement	——	——	——	——	——
Increase Decrease In Contract With Customer Liability	-$3.84M-0.6%	-$3.82M-210%	$3.47M-65.9%	$10.17M-40.6%	$17.11M-28.5%
Free cash flow	-$52.29M-10.7%	-$47.22M-9.8%	-$43.01M—	——	——
Free cash flow	-$52.29M-10.7%	-$47.22M-9.8%	-$43.01M—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Aclaris Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Aclaris Therapeutics generate?: Aclaris Therapeutics (ACRS) generated -$52.2M in operating cash flow over the trailing twelve months.
What is Aclaris Therapeutics's free cash flow?: After $81.0K of capital expenditures, Aclaris Therapeutics's free cash flow was -$52.3M over the trailing twelve months, up 5.4% year over year.
Where does Aclaris Therapeutics's cash flow data come from?: Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.